LEMBOREXANT

Lemborexant is a dual orexin receptor antagonist promoting sleep onset and maintenance. Benefits include improved sleep continuity. Side effects include nextday drowsiness, impaired driving ability, nightmares, and rare complex sleep behaviors. Only GMP materials will be supplied, logistics all according to GDP.

Product Description


Mechanism of Action

LEMBOREXANT demonstrates a highgranularity biochemical interaction profile spanning catalyticdomain modulation, multilayer signalling interference, mitochondrialnetwork recalibration, redoxstate restructuring, ionflux redistribution, membraneelectrochemical modulation, cytoskeletalarchitecture remodelling and transcriptionfactor axis reprogramming. Its molecular topology supports interactions with catalytic residues, allosteric regulatory surfaces, transmembrane helices, hydrophobic receptor pockets, nucleotidebinding cavities, redox-buffer modules and polymeric scaffolding proteinsenabling broad influence across metabolic, genomic, electrophysiological and structural regulatory networks.

Mechanistically, LEMBOREXANT may reshape phosphorylationflow geometry across ERK/MAPK/JNK/p38 cascades, modulate PI3KAKT survivalpathway architecture, alter Gprotein coupling logic, redistribute Ca²⁺ microdomains, shift IP/DAG signal amplitude, and recalibrate cAMPPKA oscillatory behaviour. Mitochondrial effects include ETCcomplex rebalancing, ATP/ADP flux modulation, ROSthreshold displacement, mitochondrialmembrane potential polarity shifts and ERmitochondria bidirectional stresssignal integration.

Advanced

  • Kinomescale catalyticcascade interference and pathway reconstruction
  • Ultraresolution receptor/ligand docking and conformationaltransition modelling
  • UPR/ERstress, mitophagy, autophagy and oxidativestress crosstalk research
  • Deep multiomics network reconstruction (RNAseq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal tensionmapping, polymer turnover and mechanosignalling analytics
  • Apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos modelling
  • Machinelearning SAR/QSAR pipelines for predictive molecular optimisation

Toxicodynamics & Hazard Spectrum

  • Rapid ROS accumulation and antioxidantbuffer system collapse
  • Mitochondrial fragmentation, membranepotential failure or ETC inhibition
  • Severe Na⁺/K⁺/Ca²⁺ ionhomeostasis disruption
  • Cytoskeletal depolymerisation, actin/tubulin instability and loss of cellular mechanics
  • membrane-integrity failure and lipidbilayer thinning
  • NF-κB, STAT and IRF inflammatoryaxis hyperactivation
  • Engagement of multiaxis programmed-cell-death pathways
  • Epigenetic drift across methylation/acetylation domains

For expert laboratory research only not intended for biological or therapeutic exposure.

Only GMP materials will be supplied, logistics all according to GDP.

Datasheet


Molecular Formula

C22H20F2N4O2

Molecular Weight

410.4 g/mol

CAS Number

1369764-02-2

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Lemborexant; 1369764-02-2; Dayvigo; E-2006; E2006

IUPAC/Chemical Name

cis-(1R,2S)-2-[(2,4-dimethylpyrimidin-5-yl)oxymethyl]-2-(3-fluorophenyl)-N-(5-fluoro-2-pyridinyl)cyclopropane-1-carboxamide

InChl Key

MUGXRYIUWFITCP-PGRDOPGGSA-N

InChl Code

InChI=1S/C22H20F2N4O2/c1-13-19(11-25-14(2)27-13)30-12-22(15-4-3-5-16(23)8-15)9-18(22)21(29)28-20-7-6-17(24)10-26-20/h3-8,10-11,18H,9,12H2,1-2H3,(H,26,28,29)/t18-,22+/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/56944144;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download